Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors (vol 20, pg 233, 2014)

被引：1
|
作者：
Rodon, Jordi [1 ,2 ]
Shapiro, G., I
Bedell, C.
Kwak, E. L.
Baselga, J.
Brana, I
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Univ Autonoma Barcelona, E-08193 Barcelona, Spain
来源：
CLINICAL CANCER RESEARCH | 2015年 / 21卷 / 09期
关键词：
D O I：
10.1158/1078-0432.CCR-15-0185
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2192 / 2192
页数：1
相关论文
共 50 条
  • [41] A phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL)
    Song, Y.
    Liu, W.
    Niu, Y.
    Cisternas, G.
    Huang, F.
    Garcia-Vargas, J.
    Childs, B. H.
    Mehra, A.
    Li, T.
    Hiemeyer, F.
    Zhai, J.
    Reschke, S.
    Granvil, C.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1344 - S1344
  • [42] A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer
    Brisson, Ryan J.
    Kochanny, Sara
    Arshad, Saba
    Dekker, Allison
    DeSouza, Jonas A.
    Saloura, Vassiliki
    Vokes, Everett E.
    Seiwert, Tanguy Y.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (11): : 3842 - 3849
  • [43] Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
    Eskens, Ferry A. L. M.
    Ramos, Francisco J.
    Burger, Herman
    O'Brien, James P.
    Piera, Adelaida
    de Jonge, Maja J. A.
    Mizui, Yoshiharu
    Wiemer, Erik A. C.
    Carreras, Maria Josepa
    Baselga, Jose
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6296 - 6304
  • [44] First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
    Brunetto, Andre T.
    Ang, Joo Ern
    Lal, Rohit
    Olmos, David
    Molife, L. Rhoda
    Kristeleit, Rebecca
    Parker, Ann
    Casamayor, Isabel
    Olaleye, Muyibat
    Mais, Anna
    Hauns, Bernhard
    Strobel, Vera
    Hentsch, Bernd
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2013, 19 (19) : 5494 - 5504
  • [45] A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
    Choudhury, Atish D.
    Higano, Celestia S.
    de Bono, Johann S.
    Cook, Natalie
    Rathkopf, Dana E.
    Wisinski, Kari B.
    Martin-Liberal, Juan
    Linch, Mark
    Heath, Elisabeth I.
    Baird, Richard D.
    Garcia-Carbacho, Javier
    Quintela-Fandino, Miguel
    Barry, Simon T.
    de Bruin, Elza C.
    Colebrook, Steve
    Hawkins, George
    Klinowska, Teresa
    Maroj, Brijesh
    Moorthy, Ganesh
    Mortimer, Peter G.
    Moschetta, Michele
    Nikolaou, Myria
    Sainsbury, Liz
    Shapiro, Geoffrey I.
    Siu, Lillian L.
    Hansen, Aaron R.
    CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2257 - 2269
  • [46] Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors
    Ando, Yuichi
    Iwasa, Satoru
    Takahashi, Shunji
    Saka, Hideo
    Kakizume, Tomoyuki
    Natsume, Kazuto
    Suenaga, Naoko
    Quadt, Cornelia
    Yamada, Yasuhide
    CANCER SCIENCE, 2019, 110 (03) : 1021 - 1031
  • [47] Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
    Ana C. Garrido-Castro
    Cristina Saura
    Romualdo Barroso-Sousa
    Hao Guo
    Eva Ciruelos
    Begoña Bermejo
    Joaquin Gavilá
    Violeta Serra
    Aleix Prat
    Laia Paré
    Pamela Céliz
    Patricia Villagrasa
    Yisheng Li
    Jennifer Savoie
    Zhan Xu
    Carlos L. Arteaga
    Ian E. Krop
    David B. Solit
    Gordon B. Mills
    Lewis C. Cantley
    Eric P. Winer
    Nancy U. Lin
    Jordi Rodon
    Breast Cancer Research, 22
  • [48] First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies
    Munster, Pamela
    Aggarwal, Rahul
    Hong, David
    Schellens, Jan H. M.
    van der Noll, Ruud
    Specht, Jennifer
    Witteveen, Petronella O.
    Werner, Theresa L.
    Dees, E. Claire
    Bergsland, Emily
    Agarwal, Neeraj
    Kleha, Joseph F.
    Durante, Michael
    Adams, Laurel
    Smith, Deborah A.
    Lampkin, Thomas A.
    Morris, Shannon R.
    Kurzrock, Razelle
    CLINICAL CANCER RESEARCH, 2016, 22 (08) : 1932 - 1939
  • [49] Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
    Garrido-Castro, Ana C.
    Saura, Cristina
    Barroso-Sousa, Romualdo
    Guo, Hao
    Ciruelos, Eva
    Bermejo, Begona
    Gavila, Joaquin
    Serra, Violeta
    Prat, Aleix
    Pare, Laia
    Celiz, Pamela
    Villagrasa, Patricia
    Li, Yisheng
    Savoie, Jennifer
    Xu, Zhan
    Arteaga, Carlos L.
    Krop, Ian E.
    Solit, David B.
    Mills, Gordon B.
    Cantley, Lewis C.
    Winer, Eric P.
    Lin, Nancy U.
    Rodon, Jordi
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [50] A PHASE I DOSE ESCALATION AND EXPANSION TRIAL OF BKM120, AN ORAL PAN-PI3K INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS: ANALYSIS OF PHARMACODYNAMIC BIOMARKER DATA
    Rodon, J.
    Bendell, J.
    Razak, A. R. A.
    De Jonge, M. J. A.
    Eskens, F.
    Di Tomaso, E.
    Sternberg, D. W.
    Wang, L.
    Sarr, C.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 158 - 159
12345